Background. We have previously shown that increasing myocardial carnitine levels in fatty acidperfused isolated working rat hearts dramatically increases glucose oxidation rates. Since high levels of fatty acids depress reperfusion recovery of ischemic hearts by inhibiting glucose oxidation, we determined what effect carnitine has on glucose oxidation during reperfusion of ischemic hearts.
he contribution of free fatty acids to myocardial ischemic injury has received considerable attention. High levels of fatty acids are purported to contribute to infarct size and mortality in humans (see References 1 and 2 for reviews) and have been shown to ischemic myocardium. Studies in humans have shown that in patients with angina pectoris and coronary artery disease, intravenous administration of L-carnitine reduces ST segment elevation and improves both atrial pacing tolerance and myocardial lactate extraction. [16] [17] [18] [19] [20] In open-chest anesthetized dogs, an intracoronary infusion of L-carnitine reduces ST segment elevation, partially restores high-energy phosphates, and prevents the incidence of ventricular fibrillation.2' In the fatty acidsupplemented porcine heart, L-carnitine improves overall hemodynamic and mechanical function,22 whereas L-propionylcarnitine partially restores depletion of tissue carnitines and reduces the uptake of free fatty acids into the myocardium. [23] [24] [25] In ischemic hearts, L-carnitine prevents the loss of tissue carnitines, decreases the grade of ventricular arrhythmias,26 and raises the atrial fibrillatory threshold.27 In isolated rat hearts, L-carnitine, L-propionylcarnitine, and L-acetylcarnitine have also been shown to improve overall mechanical function in hearts reperfused after a period of transient ischemia. 28 The mechanism for the beneficial effects of L-carnitine in ischemic hearts has not been completely delineated, but it is generally believed to be related to the actions of carnitine in modulating the transport of long-chain fatty acids across the mitochondrial matrix to the site of 3-oxidation. The commonly proposed theory to explain the actions of carnitine in the ischemic myocardium is to stimulate carnitine palmitoyltransferase I activity and thereby prevent the accumulation of potentially toxic esters of coenzyme A (CoA) and carnitine. [29] [30] [31] Increased levels of long-chain acyl-CoA have been suggested to inhibit the mitochondrial ATP translocase, thereby limiting ATP supply.29,30 However, no consistent correlation between the reported effects of carnitine on the intermediates of fatty acids and myocardial ATP content has been found. 6,7"15,32-34 In addition to carnitine's well-documented role in the oxidation of fatty acids, it can also buffer the intramitochondrial acetyl-CoA/CoA ratio by stimulating acetylcarnitine synthesis from carnitine acetyltransferase. 35 In heart mitochondria, carnitine increases CoA levels and reduces acetyl-CoA levels, resulting in a 10-to 20-fold reduction in the acetyl-CoA/CoA ratio, which correlates with an efflux of acetylcarnitine from the mitochondria.36 '37 In the intact working rat heart, we have demonstrated that this stimulates the pyruvate dehydrogenase complex activity and thereby overcomes fatty acid inhibition of glucose oxidation.'5 As a result, we believe that this role of carnitine is an alternative explanation for the beneficial effects of carnitine in the reperfused ischemic heart.
In this study, we used the isolated working rat heart to determine the effects of carnitine treatment on myocardial glucose use during reperfusion of ischemic hearts. To perform these experiments, hearts were initially perfused as described for a period of 60 minutes in the presence of 10 mM L-carnitine to increase intracellular carnitine content. ' 
Heart Perfusions
Hearts from sodium pentobarbital-anesthetized male Sprague-Dawley rats were excised, the aorta was cannulated, and a retrograde perfusion with Krebs-Henseleit buffer (pH 7.4, gassed with 95% 02/5% CO2 and containing 1.25 mM Ca21) was initiated as previously described.38 During this initial perfusion, the hearts were trimmed of excess tissue, the pulmonary artery was cut, and the opening to the left atrium was cannulated. Hearts were then switched to the working mode and perfused at an 11.5-mm Hg left atrial filling pressure and 80-mm Hg hydrostatic aortic afterload in a recirculating buffer system (100 ml) containing 11 mM glucose, 1.2 mM palmitate, and 100 ,uU/ml insulin. Palmitate was prebound to 3% bovine serum albumin. A concentration of 1.2 mM palmitate was used because this concentration of fatty acid can be seen in the blood after a myocardial infarction1"8'9 or after cardiac bypass surgery." We chose to use 11 mM glucose in the perfusate because glucose uptake is saturated at this concentration and tissue glycogen levels do not decline under aerobic conditions, and because lower glycogen levels in the heart before ischemia (which occur at lower glucose levels and in the absence of fatty acids) may affect the ability of the heart to withstand the ischemic insult. In this study, spontaneously beating hearts were used so as not to impose a high metabolic demand on hearts during the first critical minutes of reperfusion. Heart rate, peak systolic pressure development, and developed pressure were monitored throughout the perfusion with a Spectramed P 23XL pressure transducer (Oxnard, Calif.) in the aortic afterload line. Signals were recorded with a Gould RS-3600 physiograph (Cleveland, Ohio).
L-Carnitine, when used, was added to the buffer at a concentration of 10 mM at the beginning of a 60-minute aerobic baseline perfusion. This condition was chosen because carnitine uptake across the sarcolemmal membrane occurs by both a slow Na+-dependent diffusion and a carrier-mediated component.3940 We have previously shown that this 60-minute aerobic perfusion with 10 mM carnitine is sufficient to significantly increase total myocardial carnitine content.'5 A series of control and carnitine-treated hearts were also perfused for a 60-minute aerobic period. After a 5-minute drip-out period, these hearts were frozen for biochemical analysis.
Measurement of Glycolysis and Glucose Oxidation
Glycolysis and glucose oxidation were measured simultaneously by perfusing hearts with Krebs-Henseleit buffer containing 11 mM [5-3H/ul-A4C]glucose (specific activity of perfusate equaled 600,000 dpm/ml of 3H and 600,000 dpm/ml 14C), 1.2 mM palmitate, and 100 ,uU/ml insulin, as described previously. 15 Steady-state glycolytic rates were determined by measuring tritiated water production (released at the enolase step of glycolysis an oven for 12 hours at 100°C, and weighed. With the dried atrial tissue, total frozen ventricular weight, and the ventricular dry-to-wet weight ratio, the total dry weight of the heart was determined.
Measurement of Tissue Metabolites
ATP, creatine phosphate, lactate, long-chain acylCoA, and carnitine esters were extracted from frozen heart tissue by a perchloric acid extraction method described previously.38 ATP levels in neutralized extracts were determined spectrophotometrically by a coupled enzyme assay involving glucose-6-phosphate dehydrogenase and hexokinase, whereas creatine phosphate levels were determined by creatine kinase. 41 Extracted lactate levels were determined spectrophotometrically by an enzymatic assay involving glutamate pyruvate transaminase and creatine kinase.42 Longchain acyl-CoA was measured fluorometrically by an enzymatic reaction involving a-ketoglutarate dehydrogenase. 43 Long-chain acylcarnitine was hydrolyzed and free carnitine measured radioenzymatically by use of carnitine acetyltransferase. 44 
Statistical Analysis
The unpaired t test was used for the determination of statistical difference of group means. A value ofp<0.05 was considered significant. All data are presented as mean+SD.
Results

Effects of Carnitine Treatment on Myocardial Total Carnitine Content and Esters
The effects of a 60-minute aerobic baseline perfusion on total intracellular myocardial carnitine content in the presence of 10 mM L-carnitine is shown in Table 1 . Carnitine content was 4,804±358 nmol/g dry wt in control hearts, whereas in hearts perfused with carnitine, total content was 9,692±2,090 nmol/g dry wt. In these hearts, an increase in all carnitine esters was observed, including the short-chain fraction that contains acetylcarnitine. This increase in total intracellular carnitine is consistent with our previous work.15
The concentration of carnitine esters was also measured in hearts after the 40-minute period of reperfusion after ischemia ( 
Effects of Carnitine Treatment on Reperfusion Recovery of Ischemic Hearts
The effects of carnitine treatment on mechanical function in hearts subjected to a 35-minute period of ischemia is shown in Figure 1 and Table 2 . Control hearts subjected to 35 minutes of no-flow ischemia recovered only 44% of preischemic heart function. This was reflected by decreases in the recovery of both heart rate and peak systolic pressure. In carnitine-treated hearts, a significant and dramatic improvement in postischemic mechanical recovery of both heart rate and peak systolic pressure was seen. In these hearts, a 71% recovery of preischemic heart function was seen. In this study, heart rate was not controlled during the recovery period, because pacing can impose a high metabolic demand in the immediate reperfusion period and can also lead to tachycardia or fibrillation. During early reperfusion, heart rate recovered more quickly in carnitine-treated heart (at 5 minutes of reperfusion, heart rates were 110+80 and 185±75 beats per minute in control and carnitine-treated hearts, respectively). Heart rate in the carnitine-treated hearts remained significantly elevated throughout the reperfusion period ( Table 2) .
Effects of Carnitine Treatment on Myocardial Glucose Oxidation and Glycolysis in Nonischemic and Ischemic Reperfused Hearts
Measurements of glucose oxidation were obtained during the initial aerobic perfusion and during aerobic reperfusion of hearts after ischemia. Figure 2 shows cumulative glucose oxidation during the 40-minute period after ischemia. Glucose oxidation rates in both control and carnitine-treated hearts were found to be linear between 10 and 40 minutes. Steady-state rates of glucose oxidation in nonischemic hearts and in hearts reperfused after ischemia are shown in Figure 3 . In control hearts, glucose oxidation recovered to preischemic rates. Carnitine treatment resulted in a significant increase in glucose oxidation rates in nonischemic hearts. During reperfusion of ischemic hearts, carnitine treatment also stimulated glucose oxidation rates.
Rates of glycolysis were also measured in both nonischemic and reperfused ischemic hearts. Figure 4 shows cumulative glycolysis during the aerobic reperfusion of control and carnitine-treated hearts. Between 10 and 40 minutes, glycolytic rates were linear in both groups. Figure 5 shows the steady-state glycolytic rates in both nonischemic and ischemic reperfused hearts. Glycolytic rates were substantially greater than glucose oxidation rates in hearts perfused with high concentrations of fatty acids.14,15 Carnitine treatment did not dramatically alter glycolytic rates in either nonischemic or reperfused ischemic hearts. This suggests that in the intact heart, carnitine is a much more potent regulator 4.93+2.56* HR, heart rate (beats per minute); PSP, peak systolic pressure. Values are mean+SD for seven hearts in each group. Glycolysis and glucose oxidation rates are presented as rates corrected for work performed by the heart. Carnitine was added to the perfusate at a concentration of 10 mM for a period of 60 minutes. *Significant compared with control hearts under the same perfusion conditions.
nitine-treated hearts, a significant increase in glucose oxidation rates was seen during this period compared with control hearts. By 40 minutes of reperfusion, rates of glucose oxidation normalized for work were similar to rates seen in nonischemic hearts. Again, however, a significant increase in glucose oxidation was seen in carnitine-treated hearts.
Effects of Carnitine Treatment on Myocardial Levels of Long-Chain Acyl-CoA, ATP, and Lactate The beneficial effects of carnitine in the ischemic heart have often been suggested to occur secondary to a lowering of myocardial levels of long-chain acyl-CoA. Table 4 shows the effects of carnitine treatment on levels of long-chain acyl-CoA, ATP, creatine phosphate, and lactate in nonischemic and reperfused ischemic hearts. In carnitine-treated hearts, a significant increase in myocardial long-chain acyl-CoA content was observed in nonischemic hearts. This was accompanied by a slight decrease in the levels of high-energy phosphates. After perfusion of hearts with carnitine, a 5-minute Langendorff drip-out was initiated to remove any carnitine present in the extracellular space. It should be recognized that this perfusion could potentially alter the redistribution of carnitine and CoA esters. Under these conditions, a decrease in the acylation of these esters would be expected. Whether this would actually underestimate the values for these esters is uncertain.
After ischemia, carnitine treatment resulted in lower myocardial long-chain acyl-CoA levels compared with the control hearts. This was not, however, associated with any increase in myocardial ATP content. In fact, after reperfusion of previously ischemic hearts, highenergy phosphate content in carnitine-treated hearts was similar to that assayed in control hearts (Table 4) .
Lactate levels were also measured in aerobic and reperfused ischemic hearts. At the end of the aerobic perfusion, lactate levels were low in both groups. During ischemia, these levels increased to values > 120 ,umol/g dry wt.12 As expected, during reperfusion, lactate decreased in both groups. Interestingly, in carnitinetreated hearts, lactate levels were significantly lower than those seen in control hearts.
Discussion
Circulating levels of fatty acids can be markedly elevated during and after a myocardial infarction8-10 or coronary bypass surgery." Myocardial glucose oxidation and glycolysis are markedly depressed in the presence of high levels of fatty acids,14"5'45-47 primarily because of an inhibition of pyruvate dehydrogenase activated by an increase in the intramitochondrial acetylCoA/CoA and nicotinamide adenine dinucleotide reduced form/oxidized form ratios. This stimulates pyruvate dehydrogenase kinase, which phosphorylates pyruvate dehydrogenase complex and decreases the proportion of the enzyme complex in the active dephosphorylated form. High concentrations of fatty acids inhibit pyruvate dehydrogenase complex activity primarily by increasing the intramitochondrial acetyl-CoA/ CoA ratio, resulting in the dramatic decrease in glucose oxidation observed in the intact heart.6,12 '14,15 We recently demonstrated that carnitine stimulates glucose oxidation, probably by a mechanism secondary to a decrease in the intramitochondrial acetyl-CoA/CoA ratio,15 resulting in a stimulation of pyruvate dehydrogenase complex activity. Carnitine accomplishes this by binding intramitochondrial acetyl residues in the matrix, where carnitine acetyltransferase is present.35 Acetylcarnitine efflux from the matrix is then stimulated, and the acetyl group of acetylcarnitine is released in the cytosol. This frees CoA in the matrix, the net effect of which is to decrease the intramitochondrial acetyl-CoA/ CoA ratio.36 By this mechanism, increasing the availability of carnitine increases the use of glucose and suppresses the contribution of fatty acids as substrate.15
In so doing, there is a greater clearance of pyruvate from the glycolytic pathway and into the tricarboxylic acid cycle as acetyl-CoA.
A number of studies have shown that carnitine and its derivatives exert a beneficial effect in ischemic hearts. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] The mechanism by which this occurs, however, has not been delineated. It is commonly proposed that carnitine acts by preventing the loss of myocardial carnitine stores caused by esterification or membrane leakage from the ischemic tissue. Cell membrane leakage of carnitine has been suggested to lead to a disruption of the carnitine acyltransferase-translocase system, leading to adverse consequences of local accumulation of long-chain acyl-CoA and tissue free fatty acids. Another mechanism by which carnitine is suggested to be beneficial is by stimulating fatty acid oxidation, which should facilitate the removal of fatty acid intermediates that accumulate during ischemia. However, in a previous study,7 we demonstrated that a depressed recovery of coronary flow is unlikely to be a key factor in the depressed recovery of mechanical function and that after global no-flow ischemia, recovery of coronary flow occurs in parallel with recovery of mechanical function.
In carnitine-treated hearts, a significant improvement in heart rate was seen during reperfusion (Table 2 ). It is possible that this increase in heart rate in the carnitinetreated hearts could evoke the "Bowditch phenomenon," also known as the rate treppe and the staircase effect. The force-frequency relation of the Bowditch phenomenon is defined as the increase in contractile strength that accompanies frequency of stimulation. Although this can readily be seen in tissues such as ventricular trabeculae, septal preparations, and papillary muscles, it is best seen under conditions of low frequency of stimulation. In papillary muscle, an increase in force development is seen at rates of stimulation between six and 95 beats per minute, whereas at higher rates of contraction, the phenomenon is no longer observed.56 In addition, as rats grow older, they become less sensitive to the staircase effect. Ventricular trabeculae and papillary muscles from neonatal rat hearts 6 and 13 days old show positive staircase responses, with increments in stimulation of 30-90 beats per minute.57 However, if these tissues are obtained from 22-day-old rat hearts, the effect no longer persists with the same increments in stimulation. In fact, in these rats, a slight negative staircase response is seen with higher frequency of stimulation,57 indicating that the adult rat heart demonstrates an atypical forcefrequency relation, with a tendency for a decrease in contractile strength to occur with increasing frequency.56 Our earliest measurements on reperfusion recovery were obtained at 5 minutes into reperfusion, a time in which heart rate in both groups was already well above the rates at which the Bowditch phenomenon is normally seen. During this period, heart rates were 110+80 and 185+75 beats per minute for control and carnitine-treated hearts, respectively. As a result, it is unlikely that the Bowditch phenomenon is an important factor in the improved recovery of carnitine-treated hearts seen in this study.
Although the beneficial effects of carnitine on functional recovery are accompanied by a stimulation of glucose oxidation, it cannot be ruled out that it may also be acting by overcoming long-chain acyl-CoA inhibition of ATP translocase.29 '30 Although ATP levels after reperfusion were similar in control and carnitinetreated hearts, it is possible that a compartmentalization of ATP may be occurring. Unfortunately, this could not be determined in this study.
Conclusions
In conclusion, we demonstrate that the beneficial effect of carnitine on functional recovery of previously ischemic hearts perfused in the presence of fatty acids is accompanied by a stimulation in glucose oxidation. The effect of carnitine on long-chain acyl-CoA could not be correlated with high-energy phosphate content of the reperfused ischemic myocardium, thereby contradicting the commonly proposed theory of action of carnitine. Instead, we believe that the well-documented beneficial effects of carnitine on ischemic hearts is better correlated with its ability to overcome fatty acid inhibition of glucose oxidation during reperfusion.
